



## Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the (TRANS) formulary clean-up meetings held March 12, 22, 26 2021

### Background Information for our Subject Matter Experts (SMEs)

Dear Dr. Chief or Subject Matter Expert,

As part of ongoing preparations for the Odyssey build, the Pharmacy and Therapeutics Committee (PTC) is performing a formulary review in collaboration with the consulting firm Deloitte, and as endorsed by MAC.

As part of this review, select *non-formulary* drugs that are either high-cost OR for which their use-case is unclear have been identified by PTC. PTC is recommending subject matter expert (SME) review of these drugs as part of an expedited review process. In this case “high-cost” has been defined as fiscal expenditures of greater than \$5K annually. Most of these drugs have been in use over the past 2 fiscal years, but have not been submitted to PTC for consideration for addition to formulary.

We have are requesting subject matter expertise expedited review to ensure that consideration as been given to current formulary drugs or alternatives within your specialty. Drugs used significantly in both adults and pediatrics will be flagged for review by more than one Chief. The symbols (+P) will be flagged beside drugs with more use in adults and with (+A) if used more in pediatrics.

We are requesting that yourself or a delegated subject matter expert review these drugs and make recommendations as follows:

Recommendation	Explanation and notes
<b>Approve for master formulary addition, unrestricted</b>	These will be built in Odyssey, available to all prescribers
<b>Approve for master formulary addition, restricted</b>	These will be built in Odyssey, but may only be available to certain site(s) or prescriber groups (ie oncology, nephrology ,ID etc) or associated with certain funding criteria (ie. high-cost drugs in hematology with associated documentation) . We are awaiting details Odyssey about how restricted access functions, but would appreciate any suggestions you have for drugs used in your specialty
<b>Approve to build as <i>non-formulary</i></b>	These will be built in Odyssey, but requires an authorization process before dispensing
<b>Do not build</b>	These will not be built in Odyssey and will be relatively unavailable to prescribers



## Pharmacy and Therapeutics Committee

Recommendations to the Medical Advisory Committee (MAC)

From the (TRANS) formulary clean-up meetings held March 12, 22, 26 2021

P&T Motions to MAC for Approval

### 4. Motion: Subject matter expert (SME) review of the following drugs requested by respective HHS Chiefs or Delegates for the following:

- a. HHS Chief Subject Matter Expertise (SME) Requested– Drs. Khalid Azzam (Adult Medicine) and Angelo Mikrogianakis (Pediatric Medicine; denoted by “(+P)”)

Drug (generic name, trade name, strength, units)	Avg Annual RxS	Avg Annual Doses	Avg Annual \$	Suggested SME Service(s)	Approve for formulary	Approve for formulary, <i>restricted</i>	Approve as <i>non- formulary</i>	Do not build	Comments
BRIVARACETAM Brivlera 50mg TAB	32	189	\$1,252	Neurology	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Restricted to Neurology
LACOSAMIDE VIMPAT 100mg TAB (+P)	341	6121	\$18,713	Neurology + Pediatrics	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
LACOSAMIDE VIMPAT 25mg TAB.SPLIT (+P)	12	103			<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
LACOSAMIDE VIMPAT 50mg TAB (+P)	275	2835			<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MIDODRINE Amatine 2.5mg TAB	194	2766	\$6,843	Nephrology, Electrophysiology	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MIDODRINE Amatine 5mg TAB	497	8616			<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MIRABEGRON ER Myrbetriq 25mg TAB.ER	291	4324	\$14,699	Urology GIM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MIRABEGRON ER Myrbetriq 50mg TAB.ER	478	4443			<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MYCOPHENOLATE SODIUM Myfortic 180MG TAB.DR	117	1735	\$10,270	Nephrology	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
niMODipine Nimotop 30MG TAB	483	10026	\$164,894	Neurosurgery Neurology	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Restricted to Neurology
PERAMPANEL Fycompa 2mg TAB	40	195	\$7,443	Neurology	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Restricted to Neurology
RIFAXIMIN Zaxine 550mg TAB	186	3829	\$30,095	GI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Restricted to GI because of cost



**Pharmacy and Therapeutics Committee**

Recommendations to the Medical Advisory Committee (MAC)

From the (TRANS) formulary clean-up meetings held March 12, 22, 26 2021

SACCHAROMYCES BOULARDII LYO FLORASTOR 250mg CAP	401	7783	\$4,617	Infectious Diseases	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
--	-----	------	---------	------------------------	-------------------------------------	--------------------------	--------------------------	--------------------------	--



**Pharmacy and Therapeutics Committee**

Recommendations to the Medical Advisory Committee (MAC)

From the (TRANS) formulary clean-up meetings held March 12, 22, 26 2021

**b. HHS Chief Subject Matter Expertise (SME) Requested– Dr. Richard Tozer (Adult Oncology) and Angelo Mikrogianakis (Pediatric Oncology; denoted by “(+P)”)**

Drug (generic name, trade name, strength, units)	Avg Annual Rx's	Avg Annual Doses	Avg Annual \$	Suggested SME Service(s)	Approve for formulary	Approve for formulary, restricted	Approve as non-formulary	Do not build	Comments
ABIRATERONE ZYTIGA 250mg TAB	16	184	\$16,911	Oncology	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
ATOVAQUONE SUSPENSION Mepron 150mg/mL LIQ.PO	25	343	\$8,281	Infectious Diseases, Hematology	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
DEFERASIROX Jadenu 180mg TAB	4	45	\$7,673	Hematology	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MIDOSTAURIN Rydapt 25mg CAP	14	209	\$71,200	Hematology	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
TOZELLIS MOUTHWASH TOZELLIS MOUTHWASH 250mL LIQ.PO	546	1262	\$5,969	Oncology, Hematology	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
TRETINOIN Atra, Vesanoid 10MG CAP (+P)	55	502	\$35,397	Hematology, + Pediatrics	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
URSODIOL Urso, Ursofalk 250mg TAB	358	9326	\$10,141	Hematology (TLS)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Also used by GI

**c. HHS Chief Subject Matter Expertise (SME) Requested– Dr. Stephen Kelly (Surgery)**

Drug (generic name, trade name, strength, units)	Avg Annual Rx's	Avg Annual Doses	Avg Annual \$	Suggested SME Service(s)	Approve for formulary	Approve for formulary, restricted	Approve as non-formulary	Do not build	Comments
MIRABEGRON ER Myrbetriq 25mg TAB.ER	291	4324	\$14,699	Urology	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
MIRABEGRON ER Myrbetriq 50mg TAB.ER	478	4443			<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
niMODipine Nimotop 30MG TAB	483	10026	\$164,894	Neurosurgery	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	